Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Axogen

Axogen Smashes 52-Week High On FDA Nod For Breakthrough Nerve Repair Treatment

The U.S. Food and Drug Administration (FDA) on Wednesday approved Axogen Inc.’s (NASDAQ:AXGN) Biologics License Application for Avance, an acellular nerve scaffold for adult and pediatric patients aged 1 month or older with sensory, mixed, and motor peripheral nerve discontinuities.

FDA Pushes Back Axogen Avance Nerve Graft Decision By 3 Months

FDA Pushes Back Axogen Avance Nerve Graft Decision By 3 Months

The U.S. Food and Drug Administration (FDA) on Monday extended the Prescription Drug User Fee Act (PDUFA) goal date for Axogen Inc.’s (NASDAQ:AXGN) Biologics License Application (BLA) for Avance Nerve Graft by three months to December 5.

Benzinga's Top Ratings Upgrades, Downgrades For May 9, 2022

Benzinga's Top Ratings Upgrades, Downgrades For May 9, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

12 Health Care Stocks Moving In Thursday's Intraday Session

Axogen: Q4 Earnings Insights

Axogen (NASDAQ:AXGN) reported its Q4 earnings results on Tuesday, February 22, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Axogen beat estimated earnings by 38.46%, reporting an EPS of $-0.08 versus an estimate of $-0.13.

1

Organisations

B of A Securities

Truist Securities

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

Prescription Drug

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play